From recent awards, new partnerships, and scientific publications to press releases and new content about the future of diagnostics and monitoring of neurocognitive disorders
Unequal access to cognitive healthcare is a key barrier to reducing the ever-increasing rates of brain and neurodegenerative health disorders worldwide.
ViewMind, a Luxembourg startup active in precision diagnosis of neurocognitive disorders based on eye tracking movements, won the 1st place at the 14th Healthcare Innovation…
An unmatched tool for early detection of cognitive alterations
CEO of ViewMind Inc, Mark Edwards, discusses the cognitive effects of Long COVID, aiming to understand the science behind brain fog and other COVID symptoms
Digital biomarker can identify which cases of mild cognitive impairment will develop into Alzheimer’s so that early interventions can be put in place to prevent…
It has been a privilege for ViewMind Inc.
to have been a part of the CDLWisconsin, creative destruction lab program
Digital biomarker predicts mild cognitive impairment conversion to Alzheimer’s Homepage >> News >> Digital biomarker predicts mild cognitive impairment conversion to Alzheimer’s Digital biomarker
ViewMind Inc. is featured today on CBS News Homepage >> News >> ViewMind Inc. is featured today on CBS News Click to read the news Related
Cracking the cognitive effects of Long COVID Homepage >> News >> Cracking the cognitive effects of Long COVID CEO of ViewMind Inc, Mark Edwards,
The Race Against Long-Covid Homepage >> News >> The Race Against Long-Covid The Race against Long-Covid – By Leesa Soulodre Click to read the
An unmatched tool for early detection of cognitive alterations
Unequal access to cognitive healthcare is a key barrier to reducing the ever-increasing rates of brain and neurodegenerative health disorders worldwide.
ViewMind Inc. is greatly honored to have been awarded 1st place by the judges at the final of the 14th
Brain Health for Life
Easy to perform. Non-invasive.
Precision Neurology.
